Here are the principal “slide deck” visuals used to introduce Imagion Biosystems to investors prior to the company’s initial public offering on the Australian Securities Exchange. (download 4.1 MB pdf)
Imagion Biosystems HER2 Breast Cancer Program Update
Key Highlights: Manufacturing of the MagSense® HER2 Breast Cancer Imaging Agent for the Phase 2 clinical trial has been completed – major milestone achieved IBX,